Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings.
Armand Van DeunValentin BolaRossin LebekeMichel KaswaMohamed Anwar HossainMourad GumusbogaGabriela TorreaBouke Catherine de JongLeen RigoutsTom DecrooPublished in: JAC-antimicrobial resistance (2022)
RR is less frequently created when rifampicin is used only during the intensive phase. Under control programme conditions, the RIF-ADR rate for the WHO 6 month rifampicin daily regimen was as low as in affluent settings. For RR-TB control, first-line regimens should be sturdy with optimal rifampicin protection. RIF-ADR prevention is most needed where isoniazid-polyresistance is high, (re)infection control where crowding is extreme.